The purpose of the study was to develop an optimized thermoreversible controlled release gel of amide group anesthetic agent for delivery into nasal mucosal pocket containing bupivacaine hydrochloride as a model drug. The prepared formulations are biocompatible and display low viscosity at the moment of in-vivo application. Once applied, formulation undergoes a sol-gel transition, resulting in semisolid gel. Thermosensitive controlled release gel containing 5% w/v bupivacaine hydrochloride was formulated by cold method using different combination of pluronic F 127, F 87, F 108 and F 68. The gels were evaluated for drug content, gelation temperature, viscosity, in-vitro release and ex-vivo evaluation of safety and efficacy of optimized formulation. The gelation of system at body temperature is important evaluation parameter in optimization study. The formulations containing 20% w/v of pluronic F 127, F 87, F 108 and 20% w/v of pluronic F 68 showed gelation near to body temperature. The drug release from the formulations was diffusion controlled without swelling. Ex-vivo evaluation of optimized formulation was carried in horizontal ussing chamber. Optimized formulation Af4, Af10, Af16 showed promising finding in management of pain associated with scaling and root planning. Site specific delivery of anesthesia with longer duration of action was achieved with thermoreversible gel.
Loading....